MetaCap

Amphastar Pharmaceuticals (AMPH) vs Generate Biomedicines (GENB)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Generate Biomedicines is the larger company by market cap ($1.23 billion vs $1.20 billion), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

AMPH+39.64%GENB-24.58%
+65%+18%-29%
Feb 27, 20261 yearNov 20, 2026
AMPH+39.64%GENB-24.58%
+49%+10%-28%
Feb 23, 20265 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

AMPH versus GENB key metrics
MetricAMPHGENB
Share price$28.25$9.54
Market cap$1.20B$1.23B
1-day change+0.50%-8.00%
YTD return+5.49%—
1-year return+8.61%—
5-year return+41.89%—
P/E ratio (TTM)12.96—
Forward P/E8.43—
EPS (TTM)$2.18$-2.49
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$719.89M—
Revenue growth (YoY)-1.65%—
Net income (latest FY)$98.09M—
Gross margin49.46%—
Operating margin19.50%—
Net margin13.63%—
52-week high$31.00$22.67
52-week low$16.65$9.40
Distance from 52-week high-8.87%-57.92%
Analyst consensusholdstrong_buy
Avg. price target upside-13.27%+183.02%
Average volume475.35K1.24M
Shares outstanding42.65M129.10M
Employees1,976312
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About Amphastar Pharmaceuticals

AMPH stock →

Amphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a dry nasal spray used in an emergency for the treatment of severe hypoglycemia; Primatene MIST, an epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Glucagon for injection emergency kit; Enoxaparin, an injectable form of low molecular weight heparin for the prevention and treatment of deep vein thrombosis; and REXTOVY and Naloxone for opioid overdose.

Health Care · Biotechnology: Pharmaceutical Preparations · 1,976 employees

About Generate Biomedicines

GENB stock →

Generate Biomedicines, Inc., engaged in the field of generative biology by using machine learning for drug discovery and development through the programming of novel protein therapeutics in the United States. It uses protein-based modalities for drug development.

Health Care · Biotechnology: Pharmaceutical Preparations · 312 employees

AMPH vs GENB FAQ

Which is bigger, Amphastar Pharmaceuticals or Generate Biomedicines?

Generate Biomedicines (GENB) is larger, with a market capitalization of $1.23B compared with $1.20B for Amphastar Pharmaceuticals (AMPH).

Are Amphastar Pharmaceuticals and Generate Biomedicines in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons